Terumo to acquire OrganOx, maker of organ preservation devices, marking strategic entry into organ transplantation market

MedTech Intelligence – Read More

Summary:

OrganOx Limited, established in 2008 and based in Oxford, UK., manufactures organ preservation devices.
Terumo aims to enter the organ transplantation sector, addressing the shortage of available organs; approximately 6,000 patients in the U.S. die annually waiting for transplants while high rates of unused donated organs contribute to this shortage.
OrganOx specializes in Normothermic Machine Perfusion (NMP) technology, improving organ preservation and monitoring, and its liver NMP device has been used in over 6,000 procedures and received FDA approval in 2021.
Post-acquisition, Terumo will own 100% of OrganOx’s shares.

Press Release: MTI Staff was not involved in writing this content

OXFORD, United Kingdom and MADISON, N.J., Aug. 24, 2025 (GLOBE NEWSWIRE) — Terumo Corporation today announced that Terumo has entered into a definitive agreement dated August 23, 2025, with OrganOx Limited (“OrganOx” or the “Company”), a leading innovator in organ preservation devices, and its shareholders to acquire all outstanding shares of OrganOx. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The total transaction value is approximately USD $1.5 billion^*1.

Founded in 2008 by Professor Peter Friend and Professor Constantin Coussios as a spin-off from the University of Oxford, OrganOx is a pioneering medical technology company specializing in advanced organ preservation devices for Normothermic Machine Perfusion (NMP). NMP and other ex-vivo machine perfusion (EVMP) technologies can preserve organs longer by circulating oxygen and nutrient rich perfusate through the organ at near-body temperature. In addition, NMP devices enable real-time monitoring of organ condition during storage and transport. This aims to help prevent the transplantation of organs with impaired function—with the goal of improving transplant success rates—as well as leading to a more effective use of organs from marginal donors.

The acquisition marks Terumo’s strategic entry into the organ transplantation-related sector—a field with significant unmet medical needs and strong growth potential. By combining Terumo’s long-standing expertise in designing medical devices and equipment with OrganOx’s advanced capabilities in NMP, the Company aims to deliver innovative organ preservation devices globally. Terumo seeks to broaden access for patients in need of transplants and contribute to the advancement of transplantation medicine, by aiming to address key challenges in organ transplantation, including improving organ utilization rates, enabling the use of marginal donor^*2 organs, enhancing post-transplant outcomes, and reducing the burden on healthcare professionals through minimizing nighttime and emergency procedures.

“OrganOx is a pioneer and leader in organ transplantation technology,” said Oern R. Stuge MD, MBA, and Executive Chairman of OrganOx. “Today’s announced transaction is expected to expand the adoption of our transplantation technology platform by leveraging Terumo’s global infrastructure to benefit more patients around the globe.”

Terumo has built a strong relationship with OrganOx through active collaboration over the years and strengthened this partnership through a strategic investment made in March 2025 via its corporate venture capital arm, Terumo Ventures.

The post Terumo to acquire OrganOx, maker of organ preservation devices, marking strategic entry into organ transplantation market appeared first on MedTech Intelligence.